These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

445 related articles for article (PubMed ID: 32861197)

  • 1. Gut mycobiome and its interaction with diet, gut bacteria and alzheimer's disease markers in subjects with mild cognitive impairment: A pilot study.
    Nagpal R; Neth BJ; Wang S; Mishra SP; Craft S; Yadav H
    EBioMedicine; 2020 Sep; 59():102950. PubMed ID: 32861197
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Modified Mediterranean-ketogenic diet modulates gut microbiome and short-chain fatty acids in association with Alzheimer's disease markers in subjects with mild cognitive impairment.
    Nagpal R; Neth BJ; Wang S; Craft S; Yadav H
    EBioMedicine; 2019 Sep; 47():529-542. PubMed ID: 31477562
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gut Microbiome Features of Chinese Patients Newly Diagnosed with Alzheimer's Disease or Mild Cognitive Impairment.
    Guo M; Peng J; Huang X; Xiao L; Huang F; Zuo Z
    J Alzheimers Dis; 2021; 80(1):299-310. PubMed ID: 33523001
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mild cognitive impairment has similar alterations as Alzheimer's disease in gut microbiota.
    Li B; He Y; Ma J; Huang P; Du J; Cao L; Wang Y; Xiao Q; Tang H; Chen S
    Alzheimers Dement; 2019 Oct; 15(10):1357-1366. PubMed ID: 31434623
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of a ketogenic and low-fat diet on the human metabolome, microbiome, and foodome in adults at risk for Alzheimer's disease.
    Dilmore AH; Martino C; Neth BJ; West KA; Zemlin J; Rahman G; Panitchpakdi M; Meehan MJ; Weldon KC; Blach C; Schimmel L; Kaddurah-Daouk R; Dorrestein PC; Knight R; Craft S;
    Alzheimers Dement; 2023 Nov; 19(11):4805-4816. PubMed ID: 37017243
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Modified ketogenic diet is associated with improved cerebrospinal fluid biomarker profile, cerebral perfusion, and cerebral ketone body uptake in older adults at risk for Alzheimer's disease: a pilot study.
    Neth BJ; Mintz A; Whitlow C; Jung Y; Solingapuram Sai K; Register TC; Kellar D; Lockhart SN; Hoscheidt S; Maldjian J; Heslegrave AJ; Blennow K; Cunnane SC; Castellano CA; Zetterberg H; Craft S
    Neurobiol Aging; 2020 Feb; 86():54-63. PubMed ID: 31757576
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Injury markers but not amyloid markers are associated with rapid progression from mild cognitive impairment to dementia in Alzheimer's disease.
    van Rossum IA; Visser PJ; Knol DL; van der Flier WM; Teunissen CE; Barkhof F; Blankenstein MA; Scheltens P
    J Alzheimers Dis; 2012; 29(2):319-27. PubMed ID: 22233766
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association between Cerebrospinal Fluid Biomarkers for Alzheimer's Disease, APOE Genotypes and Auditory Verbal Learning Task in Subjective Cognitive Decline, Mild Cognitive Impairment, and Alzheimer's Disease.
    Mandecka M; Budziszewska M; Barczak A; Pepłońska B; Chodakowska-Żebrowska M; Filipek-Gliszczyńska A; Nesteruk M; Styczyńska M; Barcikowska M; Gabryelewicz T
    J Alzheimers Dis; 2016 Jul; 54(1):157-68. PubMed ID: 27472875
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ApoE4 effects on automated diagnostic classifiers for mild cognitive impairment and Alzheimer's disease.
    Apostolova LG; Hwang KS; Kohannim O; Avila D; Elashoff D; Jack CR; Shaw L; Trojanowski JQ; Weiner MW; Thompson PM;
    Neuroimage Clin; 2014; 4():461-72. PubMed ID: 24634832
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rapid progression from mild cognitive impairment to Alzheimer's disease in subjects with elevated levels of tau in cerebrospinal fluid and the APOE epsilon4/epsilon4 genotype.
    Blom ES; Giedraitis V; Zetterberg H; Fukumoto H; Blennow K; Hyman BT; Irizarry MC; Wahlund LO; Lannfelt L; Ingelsson M
    Dement Geriatr Cogn Disord; 2009; 27(5):458-64. PubMed ID: 19420940
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Decreasing body mass index is associated with cerebrospinal fluid markers of Alzheimer's pathology in MCI and mild dementia.
    Mathys J; Gholamrezaee M; Henry H; von Gunten A; Popp J
    Exp Gerontol; 2017 Dec; 100():45-53. PubMed ID: 29054536
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Host Factors Associated with Gut Mycobiome Structure.
    Szóstak N; Handschuh L; Samelak-Czajka A; Tomela K; Schmidt M; Pruss Ł; Milanowska-Zabel K; Kozlowski P; Philips A
    mSystems; 2023 Apr; 8(2):e0098622. PubMed ID: 36786595
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gut Microbiota Composition Is Related to AD Pathology.
    Verhaar BJH; Hendriksen HMA; de Leeuw FA; Doorduijn AS; van Leeuwenstijn M; Teunissen CE; Barkhof F; Scheltens P; Kraaij R; van Duijn CM; Nieuwdorp M; Muller M; van der Flier WM
    Front Immunol; 2021; 12():794519. PubMed ID: 35173707
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Alterations of the gut mycobiome in patients with MS.
    Shah S; Locca A; Dorsett Y; Cantoni C; Ghezzi L; Lin Q; Bokoliya S; Panier H; Suther C; Gormley M; Liu Y; Evans E; Mikesell R; Obert K; Salter A; Cross AH; Tarr PI; Lovett-Racke A; Piccio L; Zhou Y
    EBioMedicine; 2021 Sep; 71():103557. PubMed ID: 34455391
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association between Gut Microbiota with Mild Cognitive Impairment and Alzheimer's Disease in a Thai Population.
    Wanapaisan P; Chuansangeam M; Nopnipa S; Mathuranyanon R; Nonthabenjawan N; Ngamsombat C; Thientunyakit T; Muangpaisan W
    Neurodegener Dis; 2022; 22(2):43-54. PubMed ID: 36070704
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combination of gut microbiota and plasma amyloid-β as a potential index for identifying preclinical Alzheimer's disease: a cross-sectional analysis from the SILCODE study.
    Sheng C; Yang K; He B; Du W; Cai Y; Han Y
    Alzheimers Res Ther; 2022 Feb; 14(1):35. PubMed ID: 35164860
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Varying strength of cognitive markers and biomarkers to predict conversion and cognitive decline in an early-stage-enriched mild cognitive impairment sample.
    Egli SC; Hirni DI; Taylor KI; Berres M; Regeniter A; Gass A; Monsch AU; Sollberger M
    J Alzheimers Dis; 2015; 44(2):625-33. PubMed ID: 25322924
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Erlangen Score as a tool to predict progression from mild cognitive impairment to dementia in Alzheimer's disease.
    Baldeiras I; Santana I; Leitão MJ; Vieira D; Duro D; Mroczko B; Kornhuber J; Lewczuk P
    Alzheimers Res Ther; 2019 Jan; 11(1):2. PubMed ID: 30611311
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Free water in gray matter linked to gut microbiota changes with decreased butyrate producers in Alzheimer's disease and mild cognitive impairment.
    Yamashiro K; Takabayashi K; Kamagata K; Nishimoto Y; Togashi Y; Yamauchi Y; Ogaki K; Li Y; Hatano T; Motoi Y; Suzuki M; Miyakawa K; Ishikawa D; Aoki S; Urabe T; Hattori N
    Neurobiol Dis; 2024 Apr; 193():106464. PubMed ID: 38452948
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The combination of apolipoprotein E4, age and Alzheimer's Disease Assessment Scale - Cognitive Subscale improves the prediction of amyloid positron emission tomography status in clinically diagnosed mild cognitive impairment.
    Ba M; Ng KP; Gao X; Kong M; Guan L; Yu L;
    Eur J Neurol; 2019 May; 26(5):733-e53. PubMed ID: 30561868
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.